GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Beilu Pharmaceutical Co Ltd (SZSE:300016) » Definitions » Total Assets

Beijing Beilu Pharmaceutical Co (SZSE:300016) Total Assets : ¥2,869.9 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Beijing Beilu Pharmaceutical Co Total Assets?

Beijing Beilu Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥2,869.9 Mil.

Warning Sign:

If a company builds assets at 13.6% a year, faster than its revenue growth rate of 5.6% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Beijing Beilu Pharmaceutical Co's average Total Assets Growth Rate was 1.40% per year. During the past 3 years, the average Total Assets Growth Rate was 4.10% per year. During the past 5 years, the average Total Assets Growth Rate was 13.60% per year. During the past 10 years, the average Total Assets Growth Rate was 17.00% per year.

During the past 13 years, Beijing Beilu Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 54.80%. The lowest was 4.10%. And the median was 15.40%.

Total Assets is connected with ROA %. Beijing Beilu Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2024 was 1.62%. Total Assets is also linked to Revenue through Asset Turnover. Beijing Beilu Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2024 was 0.07.


Beijing Beilu Pharmaceutical Co Total Assets Historical Data

The historical data trend for Beijing Beilu Pharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Beilu Pharmaceutical Co Total Assets Chart

Beijing Beilu Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,623.82 2,847.57 2,904.27 2,818.68 2,819.42

Beijing Beilu Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,877.72 2,833.82 2,871.05 2,819.42 2,869.85

Beijing Beilu Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Beijing Beilu Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=1786.312+1033.112
=2,819.4

Beijing Beilu Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=1799.301+1070.552
=2,869.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Beilu Pharmaceutical Co  (SZSE:300016) Total Assets Explanation

Total Assets is connected with ROA %.

Beijing Beilu Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=46.104/( (2819.424+2869.853)/ 2 )
=46.104/2844.6385
=1.62 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Beijing Beilu Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=207.506/( (2819.424+2869.853)/ 2 )
=207.506/2844.6385
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Beijing Beilu Pharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Beijing Beilu Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Beilu Pharmaceutical Co (SZSE:300016) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Shuiyuan West Road, Miyun District, Beijing, CHN, 100082
Beijing Beilu Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of pharmaceutical products. The products of the company are contrasted agent series, psychotropic, and hypoglycemic products which include iopamidol injection, iodixanol injection, and reglinide tablets.
Executives
Zong Li Directors, executives
Hong Cheng Jie Director
Duan Xian Zhu Directors, executives
Zhu Zhi Director
Wang Dai Xue Director
Li Hong Directors, executives
Liu Ning Directors, executives
Wu Rui Hua Directors, executives
Wu Jie Executives
Liu Dong Long Supervisors
Hong Wei Directors, executives

Beijing Beilu Pharmaceutical Co (SZSE:300016) Headlines

No Headlines